|Day Low/High||3.97 / 4.17|
|52 Wk Low/High||2.15 / 5.78|
As earnings season began this week, we focused on researching some potential new names for the model portfolio.
This name is trading higher today after reporting strong phase III trial data for one its promising new drugs.
The J.P. Morgan Healthcare Conference kicks off with a flurry of biotech company updates.
The major averages kicked off 2010 on a positive note and a new stock joined the model portfolio this week.
A clinical study shows this name's obesity drug could also help treat sleep apnea. Here's our take.
FDA will re-examine the safety of Amgen's anemia drugs, while Vivus' weight-loss drug posts win in small sleep apnea study.
Keeping an eye on 2010 as we close out a relatively uneventful week for the model portfolio.
This model portfolio name has applied for FDA approval of its obesity drug. Here are the details.
Vivus says it asked FDA for marketing approval of its obesity drug candidate Qnexa
There was surprisingly heavy news flow in the model portfolio this week, and we took profits on one holding.
One name is trading higher on news in the obesity-drug area while another trading lower after a downgrade.
Arena Pharma asks for marketing approval of lorcaserin; 2 rivals may follow suit in 2010
We used the volatility in the market this week to initiate a new position and make some moves in the model portfolio.
Arena Pharmaceuticals shares fall on Jefferies analyst 'Hold' rating, view on obesity drug
A pair of model portfolio names are trading higher today -- one on takeover rumors and the other on new analyst coverage.
This week, we freed up some cash in anticipation of further buying opportunities for the model portfolio.
In a week that ended with a positive jobs number, we continued to research potential new names for the model portfolio.
A calendar of important, potentially stock-moving biotech events for December.
We focused on researching new names for the model portfolio this week and used Friday's pullback to add shares to one holding.
Poniard faces a cash-crunch situation after a failed drug test last week.
Two model portfolio names are in the news today amid chatter on an obesity-drug study and a takeout rumor.
Shareholders are on the hook for a generous loan repayment to Cel-Sci's founder.
Safety of Abbott's Meridia may heighten concerns for all weight-loss drugs
We put some cash to work this week as the model portfolio's benchmark, the Russell 2000, fell for four straight days.
Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.
This pharmaceutical name is trading lower on the session, but we will continue to monitor the price action before taking action.
Coventry, BJ's Wholesale, Vivus, Smith International are among big market movers Wednesday
Vivus shares rise as erectable dysfunction drug avanafil meets late-stage study goal
Shares of this recent model portfolio addition are surging on strong trial results for its erectile dysfunction drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.